Novo Nordisk to promote drug to treat obesity in United States

December 29, 2014 2:42 PM

15 0

COPENHAGEN (Reuters) - Danish pharmaceutical group Novo Nordisk plans to use 500 of its 3,000-strong sales force in the United States to promote its new obesity drug, executive vice president Jakob Riis told Reuters on Monday.

The U.S. health regulator has approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating obesity, which affects one in three Americans.

Read more

To category page